MedTrace Logo

Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls

NCT02809222 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2021-04-19

No results posted yet for this study

Summary

Myelodysplastic syndromes (MDS) is a group of heterogeneous diseases characterised by the clonal evolution of dysplastic hematopoietic stem cells. This evolution is associated with accumulation of cytogenetic mutations which leads to acute myeloid leukaemia (AML). Evolution of MDS is also associated with increase of reactive oxygen species (ROS). The increase of ROS is associated with accumulation of cytogenetic mutations. Ascorbic acid (AA) is an actor of the regulation of the oxidative metabolism in the human body.

Studies showed that supplementation with AA can change the proliferation status of MDS cells. Adjuvant treatment with AA is associated with a beneficial effect on the evolution of MDS and AML. The present study aim at describing the variations of plasmatic ascorbic acid concentrations between healthy volunteers and patients with myelodysplastic syndromes advanced in their treatment or recently diagnosed during a follow-up of 12 months.

Conditions

Interventions

OTHER

Samples

Blood samples

OTHER

Quality of life questionnaire

Questionnaire to assess the quality of life of cancer patients

Sponsors & Collaborators

  • Tours Autogreffe

    collaborator UNKNOWN

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Emmanuel GYAN, MD,PhD · University Hospital, Tours

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-25
Primary Completion
2020-03-03
Completion
2021-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809222 on ClinicalTrials.gov